Pages that link to "Q29614779"
Jump to navigation
Jump to search
The following pages link to Drug repositioning: identifying and developing new uses for existing drugs (Q29614779):
Displaying 50 items.
- Genome-scale screening of drug-target associations relevant to Ki using a chemogenomics approach (Q21133651) (← links)
- A systematic screen of FDA-approved drugs for inhibitors of biological threat agents (Q21559667) (← links)
- Genome of the human hookworm Necator americanus (Q22122067) (← links)
- The genome of the blood fluke Schistosoma mansoni (Q22122228) (← links)
- Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity (Q24605869) (← links)
- A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target (Q24623736) (← links)
- Effect of nitroxoline on angiogenesis and growth of human bladder cancer (Q24629326) (← links)
- Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4) (Q24634179) (← links)
- 'RE:fine drugs': an interactive dashboard to access drug repurposing opportunities (Q24745976) (← links)
- Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality (Q24745996) (← links)
- A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers (Q26739665) (← links)
- Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders (Q26748728) (← links)
- Methods for biological data integration: perspectives and challenges (Q26778582) (← links)
- Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments (Q26995786) (← links)
- Drug repurposing and human parasitic protozoan diseases (Q26999453) (← links)
- Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis (Q27011766) (← links)
- Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease (Q27024122) (← links)
- Shifting from the single to the multitarget paradigm in drug discovery (Q27144242) (← links)
- Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening (Q27306843) (← links)
- Repositioning Clofazimine as a Macrophage-Targeting Photoacoustic Contrast Agent (Q27327281) (← links)
- ZikaVR: An Integrated Zika Virus Resource for Genomics, Proteomics, Phylogenetic and Therapeutic Analysis (Q27468686) (← links)
- A ranking method for the concurrent learning of compounds with various activity profiles (Q27902271) (← links)
- Forces influencing generic drug development in the United States: a narrative review (Q28070306) (← links)
- On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer (Q28072798) (← links)
- Cell-Based Assay Design for High-Content Screening of Drug Candidates (Q28084264) (← links)
- A magnetic nanoprobe technology for detecting molecular interactions in live cells (Q28259715) (← links)
- Repositioning of Thiourea-Containing Drugs as Tyrosinase Inhibitors (Q28270604) (← links)
- The Use of Chemical-Chemical Interaction and Chemical Structure to Identify New Candidate Chemicals Related to Lung Cancer (Q28395836) (← links)
- Todralazine protects zebrafish from lethal effects of ionizing radiation: role of hematopoietic cell expansion (Q28468674) (← links)
- Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia (Q28472176) (← links)
- Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors (Q28475474) (← links)
- Literature mining for the discovery of hidden connections between drugs, genes and diseases (Q28475561) (← links)
- Advancing drug innovation for neglected diseases-criteria for lead progression (Q28475996) (← links)
- A computational approach to finding novel targets for existing drugs (Q28476770) (← links)
- Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening (Q28477551) (← links)
- Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study (Q28477582) (← links)
- Systematic drug repositioning based on clinical side-effects (Q28478506) (← links)
- Assessing drug target association using semantic linked data (Q28480992) (← links)
- Prediction of chemical-protein interactions network with weighted network-based inference method (Q28481329) (← links)
- Identifying novel drug indications through automated reasoning (Q28481461) (← links)
- CDA: combinatorial drug discovery using transcriptional response modules (Q28482122) (← links)
- Prediction of drug-target interactions and drug repositioning via network-based inference (Q28483634) (← links)
- Lithium chloride inhibits vascular smooth muscle cell proliferation and migration and alleviates injury-induced neointimal hyperplasia via induction of PGC-1α (Q28485853) (← links)
- Benchmarking human protein complexes to investigate drug-related systems and evaluate predicted protein complexes (Q28486017) (← links)
- Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties (Q28487333) (← links)
- A semi-supervised method for drug-target interaction prediction with consistency in networks (Q28487735) (← links)
- Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases (Q28535314) (← links)
- High sensitivity of Giardia duodenalis to tetrahydrolipstatin (orlistat) in vitro (Q28535443) (← links)
- Prediction of cancer drugs by chemical-chemical interactions (Q28539449) (← links)
- Construction of drug network based on side effects and its application for drug repositioning (Q28539501) (← links)